骨肉瘤的生物学治疗进展

doi:10.11904/j.issn.1002-3070.2018.03.013

Abstract

Abstract: Osteosarcoma(OS)is a primary malignant bone tumor,characterized by a high degree of malignancy,prone to early metastasis,and poor prognosis.The survival rate of traditional surgical treatment is less than 20%.After the continuous improvement of the OS chemotherapy regimen,the 5-year survival rate of neoadjuvant chemotherapy combined with surgery-based treatment program is increased to 60%~70%.However,the current chemotherapy regimen does not increase the survival rate of patients with OS,and the prognosis is extremely poor if patients have developed chemotherapy resistance.In order to solve the“bottleneck”problem of chemotherapy,in recent years,a comprehensive treatment plan combining immunotherapy,gene therapy,targeted therapy and chemotherapy has been advocated.In this review,the progress of OS in the immunotherapy,gene therapy and targeted therapy is discussed in recent years,and summarized the treatment of OS.

Key words: Chemotherapy, Osteosarcoma, Immunotherapy, Gene therapy, Molecule targeting therapy

CLC Number:

R738.1

ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.

References

1 赵红霞,艾辉胜.肿瘤过继性细胞免疫治疗进展[J]国际免疫学杂志,2012,35(3):201-204.
2 Mesiano G,Todorovic M,Gammaitoni L,et al.Cytokine-induced killer(CIK)cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J].Expert Opin Biol Th,2012,12(6):673-684.
3 刘兵,信瑞,国维纳,等.低剂量电离辐射诱导的兴奋性效应-肿瘤免疫治疗的新希望[J].国际免疫学杂志,2013,36(4):271-275.
4 郝希山.肿瘤学[M].北京:人民卫生出版社,2010:8.
5 曹贞国.γδT细胞在细胞免疫治疗骨肉瘤中的潜在作用[J].国际肿瘤学杂志,2008,35(5):388-391.
6 李朝旭,王锐英,唐际存.Ⅰ型IFN体外增强人γδT 细胞对骨肉瘤的杀伤作用[J].中国免疫学杂志,2014,30(11):1533-1535.
7 Li Z.Potential of human γδT cells for immunotherapy of osteosarcoma[J].Mol Bio Rep.2013,40(1):427-437.
8 李冰皓,林鹏,王战,等.去甲基化诱导肿瘤特异性CD8+T细胞识别杀伤骨肉瘤[J].中华骨科杂志,2017,37(6):329-339.
9 于哲,范清宇,马保安,等.大鼠树突状细胞融合瘤苗的特异性抗骨肉瘤作用[J].癌症,2005,24(3):285-291.
10 李奕緜,常君丽,施杞,等.骨肉瘤免疫治疗的研究现状[J].癌症进展,2017,15(6):605-608.
11 Krishnadas DK,Shusterman S,Bai F,et al.A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1,MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma[J].Cancer Immunol Immunother,2015,64(10):1251-1260.
12 Strander H,Cantell K,Carlstrom G,et al.Clinical and laboratory investigations on man:Sytemic administration of potent interferon to man[J].JNCI,1973,51(3):733-742.
13 李朝旭,唐际存,叶招明.IFN-γ增强人γδ T细胞杀伤骨肉瘤细胞的研究[J].南方医科大学学报,2013,33(1):22-25.
14 蔡滕,樊根涛.干扰素在骨肉瘤治疗中的作用[J].医学研究生学报,2012,25(9):993-996.
15 Walczak H,Miller RE,Ariail K,et al.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[J].Nat Med,1999,5(2):157-163.
16 Pardo LA,Suhmer W.Eag1 as a cancer target[J].Expert Opin Ther Tar,2008,12(7):837-843.
17 Pardo LA,Suhmer W.The roles of K(+)channels in cancer[J].Nat Rev Cancer,2014,14(1):39-48.
18 曾文容,陈志达,刘庆军,等.过表达TRAIL联合特异性沉默Eag1的协同抗骨肉瘤作用[J].中国骨与关节杂志,2016,5(2):123-128.
19 Torchilin VP.Passive and active drug targeting:drug delivery to tumors as an example[J].Handb Exp Pharmacol,2010,197(197):3-53.
20 李伟,曾建成.骨肿瘤骨靶向治疗系统[J].临床医药实践杂志,2008,17(10):801-802.
21 Goldsby RE,Fan TM,Villaluna D,et al.Feasibility and does discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma:a report from the Children′s Oncology Group[J].Eur J Cancer,2013,49(10):2384-2391.
22 Yang XN,Zeng JC,Song YC,et al.Targeted antiosteosarcoma methotrexate-bisphosphonate conjugate induces apoptosis of osteosarcoma cells in vivo[J].Eur Rev Med Pharmaco,2014,18(15):2116-2123.

[1]	LIU Yishu,QU Guofan. Progress in long-chain non-coding RNA in osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 266-270.
[2]	ZHU Huanye, JIAN Yuekui, LI Bo, GAO Gan, TIAN Zhen, SHU Man. Effect of TSP-1 gene on angiogenesis of osteosarcoma and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 103-109.
[3]	LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.
[4]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[5]	QIN Lanqun, ZOU Zhengyun. Progress in chemotherapy for malignant melanoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 167-172.
[6]	CHEN Chong, WANG Jian, YANG Shuai. Effect of miR-129 on proliferation and apoptosis of osteosarcoma MG-63 cells by targeting SEPHS1 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 21-26.
[7]	CHANG Xiaoxia, SONG Bingbing, LIU Jiaren. Research progress in phytochemicals for increasing sensitivity of tumor cells to chemotherapies [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 67-72.
[8]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[9]	SUN Zugang,WANG Zhe,CHEN Huaian,LIU Shuo,MIAO Wenlong. Progress in common chronic inflammatory factors inducing bladder cancer and its immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 357-361.
[10]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[11]	YANG Wenjuan, YU Jing, HUANG Zhao, ZHANG Junhong, XIE Conghua. Correlation between the decline of severe granulocyte in the early stage of chemotherapy and the prognosis of small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 19-24.
[12]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[13]	MENG Yongsheng. Effect of lycopene on the growth of human osteosarcoma cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 506-511.
[14]	LIANG Yusi, TAN Yonggang, ZOU Huawei. Research progress on mechanism of low-dose chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 538-542.
[15]	ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.

Progress in biological treatment of osteosarcoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments